This is a StreetInsider.com Premium Only Page

Intermec (IN) – PRNewswire

Feb 16, 2021 07:30 AM InMed Announces Closing of US$4.5 Million Private Placement

Feb 11, 2021 07:30 AM InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

Feb 5, 2021 09:00 PM InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

Feb 5, 2021 09:34 AM InMed Announces US$4.5 Million Private Placement

Jan 19, 2021 02:00 PM InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

Jan 8, 2021 07:30 AM InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Jan 5, 2021 04:52 PM InMed to Participate at Virtual Conferences in January 2021

Dec 3, 2020 07:30 AM InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

Nov 25, 2020 07:30 AM InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Nov 24, 2020 08:00 PM InMed Announces Election of Directors

Nov 18, 2020 07:30 AM InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

Nov 16, 2020 11:42 AM InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

Nov 13, 2020 07:30 AM InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

Nov 12, 2020 09:10 AM InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"

Nov 5, 2020 06:21 PM InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

Nov 4, 2020 07:30 AM InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

Sep 24, 2020 07:30 AM InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Sep 22, 2020 07:30 AM InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

Sep 8, 2020 07:30 AM InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update

Sep 2, 2020 07:30 AM InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020

Jul 7, 2020 07:30 AM InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

Jun 30, 2020 06:18 PM InMed Announces Completion of Share Consolidation

Jun 24, 2020 07:30 AM InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System

Jun 19, 2020 06:20 PM InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

May 27, 2020 07:30 AM InMed Releases CBN Preclinical Results in Glaucoma

May 19, 2020 07:30 AM InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

May 14, 2020 07:30 AM InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 12, 2020 07:30 AM InMed Files PCT Patent Application for Neuroprotection in Glaucoma

May 8, 2020 07:30 AM InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

May 7, 2020 07:30 AM InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference

May 5, 2020 07:30 AM InMed and Almac Group Developing Improved Cannabinoid Production Methods

Apr 30, 2020 07:30 AM InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

Apr 1, 2020 07:30 AM InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Mar 24, 2020 07:30 AM InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

Mar 20, 2020 07:30 AM InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

Mar 10, 2020 01:24 PM InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Feb 14, 2020 07:30 AM InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

Feb 7, 2020 07:30 AM InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020

Jan 21, 2020 07:30 AM InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

Jan 20, 2020 07:30 AM InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

Jan 16, 2020 07:30 AM InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

Jan 10, 2020 05:56 PM InMed Announces Election of Directors

Jan 8, 2020 07:30 AM InMed Pharmaceuticals to Present at the Biotech Showcase Conference

Dec 9, 2019 08:35 AM Global OTCQX Consumer and Resource Company Investor Presentations Now Available for On-Demand Viewing

Dec 9, 2019 07:30 AM InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

Dec 2, 2019 08:35 AM Live Investor Conference & Webinar: A Global Portfolio of OTCQX Consumer and Resources Leaders Present December 4th and 5th

Nov 25, 2019 08:35 AM Live Investor Conference & Webinar: Executives from Resource, Retail, and Cannabis Companies Present December 4th and 5th

Nov 11, 2019 08:30 AM InMed Pharmaceuticals to Present at the Cowen Conference

Nov 8, 2019 07:30 AM InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

Nov 5, 2019 07:30 AM InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial